AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies

 AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies

AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies

Shots:

  • Caribou to receive $40M up front in cash & equity investment, ~$300M in development, regulatory, and launch milestones along with additional commercial milestones and global royalties
  • AbbVie will utilize and gets exclusive rights to Caribou’s next-generation Cas12a chRDNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies directed to specified targets
  • Caribou will responsible for pre-clinical research, development, and manufacturing activities for the collaboration programs and AbbVie will reimburse Caribou for all such activities pursuant to the deal

Click here ­to­ read full press release/ article | Ref: Abbvie | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post